Beuzit Luc, Edeline Julien, Brun Vanessa, Ronot Maxime, Guillygomarc'h Anne, Boudjema Karim, Gandon Yves, Garin Etienne, Rolland Yan
Department of Radiology, Rennes University Hospital, 2 Rue Henri Le Guilloux, 35000 Rennes, France.
Department of Medical Oncology, Comprehensive Cancer Center, Institute Eugène Marquis, Rennes, France.
Eur J Radiol. 2016 Aug;85(8):1445-52. doi: 10.1016/j.ejrad.2016.05.020. Epub 2016 Jun 2.
To compare Choi criteria with Response Evaluation Criteria in Solid Tumors (RECIST) for the prediction of overall survival (OS) in patients treated with glass-microspheres, Yttrium-90 selective internal radiation therapy (SIRT) for intrahepatic cholangiocarcinoma (ICC).
Between 2010 and 2014, 45 adult patients with locally advanced ICC treated with SIRT were retrospectively analyzed. Computed tomography scans performed before and after treatment were analyzed using both RECIST 1.1 and Choi criteria. Response was correlated with survival.
Patients who achieved an objective response according to Choi had a longer OS than non-responders (median OS 19.9 months [95% CI, 1.1-38.7 months] vs. 7.5 months if stable disease [uncountable CI] and 3 months if progressive disease [95% CI, 0-6.2 months], log-rank test: p=0.003) whereas there was no significant survival difference according to the RECIST response (p=0.339). Among the 39 RECIST non-responding patients, those identified as responders by Choi (n=31) had significantly better OS than Choi non-responders (median OS 19.9 months (95% CI, 5.1-34.7 months) and 5.4 months (95% CI, 0-11.6 months), p=0.005).
Choi criteria appear more appropriate than RECIST to identify responders with long survival among patients who received SIRT for ICC.
比较Choi标准与实体瘤疗效评价标准(RECIST)在预测接受玻璃微球钇-90选择性内放射治疗(SIRT)的肝内胆管癌(ICC)患者总生存期(OS)方面的差异。
回顾性分析2010年至2014年间45例接受SIRT治疗的局部晚期ICC成年患者。使用RECIST 1.1和Choi标准对治疗前后的计算机断层扫描进行分析。疗效与生存期相关。
根据Choi标准达到客观缓解的患者的总生存期长于未缓解者(中位总生存期19.9个月[95%CI,1.1 - 38.7个月],疾病稳定时为7.5个月[不可数CI],疾病进展时为3个月[95%CI,0 - 6.2个月],对数秩检验:p = 0.003),而根据RECIST标准的疗效差异无统计学意义(p = 0.339)。在39例RECIST标准未缓解的患者中,被Choi标准判定为缓解者(n = 31)的总生存期明显优于Choi标准未缓解者(中位总生存期19.9个月(95%CI,5.1 - 34.7个月)和5.4个月(95%CI,0 - 11.6个月),p = 0.005)。
对于接受SIRT治疗的ICC患者,Choi标准似乎比RECIST标准更适合识别生存期长的缓解者。